Lingrui Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 474 million yuan, a year-on-year increase of 14.85%
I'm PortAI, I can summarize articles.
Lingrui Pharma released its semi-annual report for 2025, with operating revenue of 2.099 billion yuan, a year-on-year increase of 10.14%; net profit attributable to shareholders of the parent company was 474 million yuan, a year-on-year increase of 14.85%; net profit excluding non-recurring gains and losses was 442 million yuan, a year-on-year increase of 12.28%; basic earnings per share were 0.836 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments